https://e-journal.unair.ac.id/JFIKI/issue/feedJURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA2024-12-13T22:14:57+07:00apt. Elida Zairina, S.Si., MPH., Ph.D.jfiki@ff.unair.ac.idOpen Journal Systems<table cellspacing="0" cellpadding="0" align="left"> <tbody> <tr> <td align="left" valign="top"> <p><a href="https://portal.issn.org/resource/ISSN/2580-8303">ISSN International Centre</a> | <a href="https://issn.brin.go.id/terbit/detail/1412835086" target="_blank" rel="noopener">ISSN: 2406-9388 (Print)</a> | <a href="https://issn.brin.go.id/terbit/detail/1468378589" target="_blank" rel="noopener">ISSN: 2580-8303 (Online)</a></p> <p>Jurnal Farmasi dan Ilmu Kefarmasian Indonesia (Pharmacy and Pharmaceutical Sciences Journal) P-ISSN: 2406-9388; E-ISSN: 2580-8303 is an official journal published by the Faculty of Pharmacy, Universitas Airlangga in collaboration with <a href="https://iaijatim.id/">Indonesian Pharmacists Association (IAI) of East Java</a> and <a href="https://www.centerforpatientsafety-indonesia.com/">Center for Patient Safety Research</a> which the articles can be accessed and downloaded online by the public (open access journal).</p> <p>This journal is a peer-reviewed journal published three times a year on topics of excellence of research results in the fields of service and practice of pharmacy, community medicine, pharmaceutical technology, and health science disciplines that are closely related. This journal accepts English texts. The following are the research areas that this journal focuses on</p> <p>1. Clinical Pharmacy<br />2. Community Pharmacy<br /><span style="font-size: 0.875rem;">3. Pharmaceutics<br /></span><span style="font-size: 0.875rem;">4. Pharmaceutical Chemistry<br /></span><span style="font-size: 0.875rem;">5. Pharmacognosy<br /></span><span style="font-size: 0.875rem;">6. Phytochemistry</span></p> <p>Jurnal Farmasi dan Ilmu Kefarmasian Indonesia (Pharmacy and Pharmaceutical Sciences Journal) receives manuscript from the results of research (research article), systematic reviews and meta analysis that are closely related to the health sector, particularly the pharmaceutical field. Selected manuscripts for publication in this journal will be sent to two reviewers expert in their field, who are not affiliated with the same institution as the author(s), and are chosen based on the consideration of the editorial team. The review process is conducted in a closed manner where the author(s) and reviewers do not know the identity and affiliation of each. Each manuscript delegated to editorial members is examined for the final decision of the review process. The author(s) are required to respond to the review given and send revised manuscripts within the allotted time after the comments and suggestions from the reviewers have been sent. Manuscripts accepted for publication are edited copies checked for the grammar, punctuation, print style, and format. The entire process of submitting the manuscripts to the final decision for publishing is done online. </p> <p>JFIKI has been indexed in <a href="https://doaj.org/toc/2580-8303?source=%7B%22query%22%3A%7B%22bool%22%3A%7B%22must%22%3A%5B%7B%22terms%22%3A%7B%22index.issn.exact%22%3A%5B%222406-9388%22%2C%222580-8303%22%5D%7D%7D%5D%7D%7D%2C%22size%22%3A100%2C%22sort%22%3A%5B%7B%22created_date%22%3A%7B%22order%22%3A%22desc%22%7D%7D%5D%2C%22_source%22%3A%7B%7D%2C%22track_total_hits%22%3Atrue%7D" target="_blank" rel="noopener">DOAJ</a>, <a href="https://sinta.kemdikbud.go.id/journals/profile/5280" target="_blank" rel="noopener">Sinta 2</a>, <a href="https://app.dimensions.ai/discover/publication?search_mode=content&search_text=Jurnal%20Farmasi%20dan%20Ilmu%20Kefarmasian%20Indonesia&search_type=kws&search_field=full_search&or_facet_source_title=jour.1301095" target="_blank" rel="noopener">Dimensions</a>, <a href="https://essentials.ebsco.com/search/eds/details/jurnal-farmasi-dan-ilmu-kefarmasian-indonesia?query=Jurnal%20Farmasi%20Dan%20Ilmu%20Kefarmasian%20Indonesia&requestCount=0&db=edsdoj&an=edsdoj.28ff8dd490e84b75b8645da7e506f18d">EBSCO</a>, and <a href="https://e-journal.unair.ac.id/JFIKI/Editorial_Policies#custom-2" target="_blank" rel="noopener">others indexing</a>. This journal has been accredited as a 2nd Grade Scientific Journal (Sinta 2) by the Ministry of Research, Technology, and Higher Education of Indonesia since 23 December 2020.</p> </td> </tr> </tbody> </table>https://e-journal.unair.ac.id/JFIKI/article/view/64894The Effect of Quercetin on Coenzyme HMG-CoAR, ABCA1 Transporter, Dyslipidemia Profile and Hepatic Function in Rats Dyslipidemia Model2024-11-25T08:53:59+07:00Ignasius Agyo Palmadoignasius.agyo.palmado-2022@ff.unair.ac.idSulistyanaengci Winartoignasius.agyo.palmado-2022@ff.unair.ac.idHoney Dzikri Marhaenyhoney.dzikri.marhaeny-2022@ff.unair.ac.idYusuf Alif Pratamayusuf.alif.pratama-2021@ff.unair.ac.idChrismawan Ardiantochrismawan-a@ff.unair.ac.idJunaidi Khotibjunaidi-k@ff.unair.ac.id<p><strong>Background: </strong>Dyslipidemia is a lipid metabolic disorder that increases the risk of cardiovascular disease, typically marked abnormality of triglycerides (TG), low-density lipoprotein (LDL) and total cholesterol (TC), along with decreased high-density lipoprotein (HDL). This research explored the potential of quercetin, a natural substance, as a preventive for dyslipidemia induced by a high-fat diet (HFD) in a rat model. Simvastatin, a standard cholesterol-lowering drug, was used for comparison. <strong>Objective: </strong>The main principle of this research was evaluating quercetin's potential in lipid metabolism for dyslipidemia caused by HFD and comparing its effects with first-line drug therapy simvastatin, which had a similar mechanism. <strong>Methods: </strong>Rats given an HFD were treated with quercetin and simvastatin, and their lipid profiles, liver enzyme activities, and molecular markers related to cholesterol metabolism were analyzed. <strong>Results: </strong>Quercetin markedly decreased cholesterol by inhibiting the enzyme 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMG CoAR). It also prevented liver damage by cellular observation and showed a protective effect on liver enzyme activity. Quercetin enhanced expression of the Adenosine Triphosphate Binding Cassette subfamily A member 1 (ABCA1) protein, showing a protective effect against dyslipidemia akin to simvastatin, yet with a reduced likelihood of liver toxicity. <strong>Conclusion: </strong>Quercetin may serve as an effective and safer alternative to simvastatin for treating dyslipidemia, offering cholesterol-lowering benefits without the hepatotoxic risks associated with long-term statin therapy.</p>2024-12-13T00:00:00+07:00Copyright (c) 2024 JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIAhttps://e-journal.unair.ac.id/JFIKI/article/view/63670In Silico Analgesic and Toxicity Analysis of Modified Paracetamol on COX-2 Receptor (PDB ID: 3LN1)2024-11-08T17:59:23+07:00Nurul Hidayahnuuurulhdyh@gmail.comLina Permatasarilina.permatasari09@gmail.comAgriana Rosmalina Hidayatilina.permatasari09@gmail.comHanda Muliasarilina.permatasari09@gmail.com<p><strong>Background</strong>: Paracetamol is still often used in Indonesia as the main analgesic. Use above 4 gram per day or a single dose above 10 gram can cause hepatotoxicity. This can be overcome by modifying the structure through a CADD (computer aided drug design) approach, especially molecular docking, aims to produce compounds with greater potency and fewer side effects. <strong>Objective</strong>: This study aimed to determine the analgesic activity and toxicity of paracetamol derivative compounds modified by the Topliss method. <strong>Methods</strong>: Analgesic activity was tested by molecular docking on COX-2 receptor (PDB ID 3LN1) using AutoDock Tool 4.2, and toxicity testing using pkCSM and Protox Online Tool. <strong>Results</strong>: The results of docking show that the free binding energy values for test compounds 1 to 5 are -10.59 kcal/mol, -10.17 kcal/mol, -8.79 kcal/mol, -10.01 kcal/mol, and -9.32 kcal/mol, respectively, with corresponding inhibition constants of 17.29 nM, 35.21 nM, 360.88 nM, 46.36 nM, and 146.65 nM. These values are lower than paracetamol which has a free binding energy of -6.21 kcal/mol and an inhibition constant of 28,043 nM. The results show that the test compound is more stable in ligand-receptor binding. Toxicity tests showed that all test compounds and paracetamol belonged to toxicity class IV. The test compound had an LD<sub>50</sub> value of 1551 mg/kg, higher than paracetamol (338 mg/kg), thus indicating better effectiveness. <strong>Conclusion</strong>: Compound 2 is predicted to have the best biological activity and potential as an alternative to paracetamol.</p>2024-12-13T00:00:00+07:00Copyright (c) 2024 JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIAhttps://e-journal.unair.ac.id/JFIKI/article/view/58733Solubilization Inclusion Bodies from Synthetic Recombinant PGA Gene Expressed in E. coli BL21(DE3) by Denaturing and Non-denaturing Agents2024-11-19T10:56:22+07:00Purwanto Purwantopurwanto_fa@ugm.ac.idSismindari Sismindarisismindari@ugm.ac.idIndah Purwantiniindahp@ugm.ac.idRumiyati Rumiyatirumiyaris@ugm.ac.idMuthi'ah Rasyidahmuthiahrsydh@gmail.comMuhammad Adi Muliaadimulia2007@gmail.com<p><strong>Background</strong>: With the rise of green chemistry, synthesis of antibiotic compounds through enzymatic process is a preferred option. Penicillin-G acylase (PGA) is an important enzyme for producing important antibiotics, such as penicillin and its derivatives. For this reason, studies on PGA have been widely carried out worldwide. In penicillin biosynthetic pathway, PGA catalyzes conversion of penicillin-G into 6-amino penicillanic acid (6-APA), a precursor for enzymatic synthesis of penicillin derivatives. Unfortunately, bacteria naturally produce the PGA enzyme in very small quantities. <strong>Objective: </strong>One strategy to produce this enzyme in larger quantities is DNA recombination, expressed in <em>E</em><em>scherichia</em><em> coli</em>. A common obstacle of protein overexpression in <em>E. coli</em> is the formation of inclusion bodies (IBs). In this study, we would like to discuss IBs solubilization methods of recombinant PGA derived from <em>E. coli</em> (rPGAEc) expressed in <em>E. coli </em>BL21 (DE3). <strong>Methods: </strong>Recombinant <em>E. coli </em>BL21 (DE3) harboring <em>rPGAEc</em> was induced by IPTG for enzyme expression. Induction was performed at 16<sup>o</sup>C for 4 h and 24 h. The PGA enzyme expressed in IBs form, was then incubated in two solutions containing 8 M urea and 0.2% sarcosine to get a soluble enzyme. <strong>Results: </strong>Based on protein analysis by SDS PAGE, a solution containing 8 M urea solubilized the PGA enzyme more abundantly than 0,2% sarcosine. <strong>Conclusion: </strong>The solubilization technique of the PGA enzyme expressed by <em>E. coli </em>proposed by this research became an alternative solution that can be considered for this purpose.</p>2024-12-13T00:00:00+07:00Copyright (c) 2024 JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIAhttps://e-journal.unair.ac.id/JFIKI/article/view/65027A Case Report of Lurasidone-Induced Tardive Dyskinesia: Therapeutic Role of Valbenazine2024-12-06T07:50:34+07:00Ambika Nand Jhanandjha99@gmail.comVarsha Ratan Gaikwadvgaikwad1906@gmail.com<p><strong>Introduction:</strong> Tardive dyskinesia (TD) is a complex, potentially irreversible movement disorder primarily associated with the long-term use of antipsychotic medications, particularly typical neuroleptic drugs. TD can develop during treatment and persist long after thediscontinuation of the culprit medication. The etiology of this condition involves dysregulation of dopaminergic signalling, especially within the striatum, leading to the activation of D2 dopamine receptors. This imbalance affects the homeostasis of neurotransmitters, including GABA and glutamate. Chronic dopamine receptor antagonism incites neuroadaptive alterations that may linger post-therapy, resulting in abnormal involuntary movements affecting the orofacial regions, limbs, and trunk, which profoundly diminishes patient quality of life. <strong>Case:</strong> A 29-year-old female with a known history of schizophrenia presented with sudden-onset neurological symptoms, notably persistent orofacial dyskinesias such as lip smacking and grimacing, which had developed over a 24-hour period. A thorough review of her medication indicated that lurasidone classified as an atypical antipsychotic, was likely responsible for the onset of these dyskinetic movement features. Consequently, the physician opted to discontinue lurasidone and initiate valbenazine at 40 mg once daily, with the intent of managing the dyskinetic symptoms while considering the overall psychiatric and medical treatment plan for the patient. <strong>Conclusion:</strong> The emergence of orofacial dyskinesias in this patient suggests a possible adverse reaction to lurasidone, necessitating re-evaluation of her psychopharmacological regimen. Valbenazine, a selective vesicular monoamine transporter 2 inhibitor, may provide a tailored approach to mitigate dyskinetic movements while maintaining therapeutic efficacy in psychiatric care.</p>2024-12-13T00:00:00+07:00Copyright (c) 2024 JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIAhttps://e-journal.unair.ac.id/JFIKI/article/view/63671Antidiarrhea Activity of Ethanol Extract of Rambutan Leaves ( Nephelium lappaceum L.) in Capsule Form on Male Mice2024-12-10T12:10:01+07:00Nitya Nurul Fadilahnityanurul@gmail.comAli Nofriyaldinityanurul@gmail.comAyu Rahmawatinityanurul@gmail.comSrie Rezeki Nur Endahnityanurul@gmail.comWidya Nurul Aininityanurul@gmail.comVincent O. Imiejenityanurul@gmail.com<p><strong><em>Background</em></strong><em>: Diarrhea characterized by changes in stool form to soft or liquid with an intensity of bowel movements more than three times a day. One of the plants used as an alternative treatment for diarrhea is rambutan, </em><em>especially its leaves</em><em>. </em><em>Rambutan leaf extract in previous studies has shown that it can treat diarrhea. </em><strong><em>Objective</em></strong><em>: The purpose of this study was to determine the antidiarrhea activity in capsules of ethanol extract of rambutan leaves containing tannins and flavonoids as antidiarrhea that inhibiting intestinal motility.</em><em> <strong>Methods</strong>: The study was conducted experimentally using the intestinal transit method, which measures the length of the intestine passed through by the marker. The smaller the ratio between the length of the intestine and the marker, the more it indicates a decrease in intestinal motility in mice.</em> <em>Group 1 loperamide HCl with a dose of 4 mg/kg </em><em>BW</em><em>, Group 2 used </em><em>placebo</em><em>, Group 3 used F</em><em>I, FII, FIII</em><em> capsules with a dose of 50 mg, 100 mg, and 150 mg. <strong>Results </strong>: The test results showed that formulation 1</em><em>, 2, 3 </em><em> had an activity of 23.3%, 26.8%, and</em> <em>32.3%. The capsule with the best results was formulation 3 with a dose of 150 mg. </em><em>Compared </em><em>to the positive control, the effectiveness of this capsule was 22% </em><em>higher than loperamide.</em> <strong><em>Conclusion</em></strong><em>: The results of</em><em> the study showed that rambutan leaves extract in capsule form effectively treat diarrhea</em><em>. T</em><em>he One Way Anova test showed a significant value between groups F</em><em>I</em><em>, F</em><em>II</em><em>, and F</em><em>III</em><em> (ρ<0.05).</em></p>2024-12-19T00:00:00+07:00Copyright (c) 2024 JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIAhttps://e-journal.unair.ac.id/JFIKI/article/view/61360A Comprehensive Evaluation of Antibiotic Usage: Establishing a Foundation for Effective Antimicrobial Stewardship 2024-12-09T22:44:50+07:00Nurma Surinurma.suri@fk.unila.ac.idMirza Junandomirzanando@gmail.comRegi Afriyanaregiafriyana06@gmail.com<p><strong><em>Background</em></strong><em>: The intensive care unit (ICU) is a significant area of antibiotic use, accounting for a substantial proportion of overall antibiotic consumption. Inappropriate use of antibiotics in such settings has a notable impact on the emergence of antimicrobial resistance. <strong>Objective</strong>: This study evaluated the rationality of antibiotic use in the ICU of RSUD Abdul Moeloek Hospital in Lampung Province. <strong>Methods</strong>:</em><em> The study was conducted between December 2022 and February 2023 using a prospective method and purposive sampling. An evaluation was conducted using the Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) system for quantitative analysis and Gyssens criteria for qualitative assessment. </em><em>The research subjects comprised 55 individuals, the majority of whom were male (58.2%), aged > 65 years (29.1%), remained in the ICU for a period of less than seven days (78.2%), and subsequently continued their treatment in a non-ICU (69.1%). <strong>Results</strong>: The results of quantitative analysis demonstrated that the total number of antibiotics administered in this study was 394.83 DDD, with a DDD/100 patient-day value of 113.78. Ceftriaxone was the most frequently prescribed antibiotic (219 DDD), whereas gentamicin was the least frequently used (1 DDD). Qualitative analysis revealed that 17.6% of the cases exhibited irrational use of antibiotics. <strong>Conclusion</strong>: Irrational use of antibiotics was observed in the following categories: IV A (1.1%), IV D (2.2%), III A (2.2%), III B (2.2%), IIA (3.3%), IIB (5.5%), and I (1.1%). </em><em>The study concluded that there is still a considerable degree of irrational antibiotic use.</em></p>2024-12-19T00:00:00+07:00Copyright (c) 2024 JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA